entertainment -WSS

entertainment

author：leisure time 2025-10-01 00:05:47 - browse：952

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： IRA could hurt research into orphan drugs for rare diseases

WSS

Allen Institute goes after foundational questions, CEO Costa says

Popular nasal decongestant doesn't actually relieve congestion

FDA proposes changes to key medical devices approval pathway

Telehealth for opioid use disorder is lifesaving

New weight loss drugs vying to be the next Wegovy or Mounjaro

FDA panel endorses Alnylam’s heart drug — after picking it apart

focus

entertainment

Wikipedia

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Arena BioWorks launches in Cambridge to speed drug discovery

Virginia high school admissions case could be legal follow

STAT Virtual Event: JPM Recap, Live!

Jerome Adams on the need for new antivirals for Covid

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Walmart eyes Medicare Advantage provider ChenMed

Cancer drug shortages should be causing more outrage

Hospital chaplains balance Covid safety with patients’ spiritual needs

leisure time

Physician assistants need a new name. Here's what it should be

Medicare Advantage coverage denials need scrutiny, senators say

Nonprofit, backed by Microsoft, to certify AI tools in health care

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Gene therapy denied for Afghan refugee whose father aided U.S.

Food makers to regulators: Ultra

hotspot

entertainment

focus

knowledge